Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright‘s price target points to a potential upside of 460.75% from the company’s current price.

COYA has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Coya Therapeutics in a report on Monday, August 24th. BTIG Research reiterated a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Coya Therapeutics Stock Performance

Shares of NASDAQ:COYA opened at $3.21 on Thursday. The company has a market capitalization of $75.31 million, a P/E ratio of -2.31 and a beta of 0.70. The company’s 50-day moving average is $4.34 and its 200 day moving average is $4.59. Coya Therapeutics has a fifty-two week low of $2.72 and a fifty-two week high of $6.62.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.11). The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative return on equity of 66.91% and a negative net margin of 643.44%. As a group, research analysts predict that Coya Therapeutics will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its position in shares of Coya Therapeutics by 205.2% during the first quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock worth $377,000 after acquiring an additional 64,490 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Coya Therapeutics in the first quarter valued at $161,000. Long Corridor Asset Management Ltd purchased a new position in shares of Coya Therapeutics in the second quarter valued at $227,000. Renaissance Technologies LLC raised its stake in shares of Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after purchasing an additional 37,064 shares during the period. Finally, AXQ Capital LP bought a new stake in shares of Coya Therapeutics during the 2nd quarter valued at $116,000. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.